Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial

S. Dent, J. Cortés, Y. H. Im, V. Diéras, N. Harbeck, I. E. Krop, T. R. Wilson, N. Cui, F. Schimmoller, J. Y. Hsu, J. He, M. De Laurentiis, S. Sousa, P. Drullinsky, W. Jacot

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial'. Together they form a unique fingerprint.

Medicine & Life Sciences